Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.2.1.31 (
beta-glucuronidase
)
7,680
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
An enzyme-linked immunosorbent assay (ELISA) was developed for human
beta-glucuronidase
, using a specific polyclonal antibody raised against the purified enzyme. beta-Glucuronidase from human liver consisted of three subunits with molecular mass of 76, 64 and 18 kDa. The assay offered a specific, sensitive and convenient means of measuring immunoreactive
beta-glucuronidase
in human sera. beta-Glucuronidase activity determined by the conventional method appeared to be extremely low, indicating that in human sera
beta-glucuronidase
exists in an enzymatically inactive form. The sensitivity of the assay permitted the detection of 1-100 ng of purified
beta-glucuronidase
. A mean serum level in normal subjects was 108 +/- 25 ng/ml (mean +/- S.D.). A high level of
beta-glucuronidase
was found in sera of patients with severe hepatocellular necrosis, including liver cirrhosis (152 +/- 130 ng/ml) and chronic active hepatitis (220 +/- 99 ng/ml), whereas no significant increase of the enzyme protein was observed in
chronic persistent hepatitis
(102 +/- 42 ng/ml). beta-Glucuronidase was also increased in sera of patients with primary hepatoma (156 +/- 125 ng/ml). The immunoreactive
beta-glucuronidase
determined in this assay was thought to be a supplementary serological indicator for hepatocellular necrosis.
...
PMID:Serum immunoreactive beta-glucuronidase determined by an enzyme-linked immunosorbent assay in patients with hepatic diseases. 163 57